European Medicines Agency (EMA) - Review underway for MS Drug Lemtrada®

15 April 2019

Following a warning late last year, European neurologists have been cautioned on the use of the MS treatment Lemtrada; while the EMA undertakes their review of side effects in some European patients.

Australian neurologists are aware of this and urge patients to continue to comply with the routine monitoring requirements we have in place in Australia (i.e. Bloodwatch). If you are currently using Lemtrada your neurologist will continue their routine follow up with you.

If you have any questions MSWA recommends you contact your treating neurologist.

Find more information on the MS Australia website here.